If the year started on a tepid note, then it certainly ended at a peak with the best quarter of the year in terms of both the deals and the total amount invested.
With its €129M funding round in the fourth quarter of 2023, Amsterdam-based VectorY Therapeutics single-handedly demonstrated interest in the life sciences sector, with it being the only deal of 2023 valued at more than 100 million euros.
[
add
]
[
|
|
...
]